1.24

12.68% -0.18

After Hours: 1.26 0.02 +1.61%

Xortx Therapeutics Inc (XRTX)

Overview News Price History Discussions Forecast Stock Split

Xortx Therapeutics Inc stock is traded at $1.24, with a volume of 91,858. It is down -12.68% in the last 24 hours and down -30.34% over the past month. XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.

Previous Close:

$1.42

Open:

$1.39

24h Volume:

91,858

Relative Volume:

0.03

Market Cap:

$2.25M

Revenue:

Net Income/Loss:

$-2.77M

P/E Ratio:

-0.4686

EPS:

-2.6464

Net Cash Flow:

$-2.69M

1W Performance:

-12.06%

1M Performance:

-30.34%

6M Performance:

-49.18%

1Y Performance:

-70.82%

1-Day Range:

$1.21

$1.4162

1-Week Range:

$1.21

$1.90

52-Week Range:

$1.21

$7.05

Xortx Therapeutics Inc Stock (XRTX) Company Profile

Name

Xortx Therapeutics Inc

Sector

Healthcare (1052)

Industry

Biotechnology (594)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-11-13

Latest SEC Filings

XRTX's Discussions on Twitter

Compare XRTX vs VRTX, MRNA, REGN, ARGX, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XRTX Xortx Therapeutics Inc	1.24	2.25M	0	-2.77M	-2.69M	-2.6464
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Xortx Therapeutics Inc Stock (XRTX) Latest News

Oct 12, 2026

Canadian testing is expected to speed data for XORTX (XRTX)'s planned U.S. gout drug application. - Stock Titan

Oct 08, 2026

Global gout cases are expected to rise 70% over 25 years. XORTX plans to apply to study a gout drug in Canada. - Stock Titan

Oct 08, 2026

Sep 21, 2026

Why XORTX Therapeutics Inc. (NASDAQ:XRTX) Is In Focus Now? - Kalkine Media

Sep 21, 2026

Sep 18, 2026

XRTX Stock Whipsaws As XORTX Ramps Gout Drug Manufacturing - StocksToTrade

Sep 18, 2026

Sep 17, 2026

XORTX (XRTX) Stock Analysis: -6.74% Down — Bearish Signals to Watch 2026-09-17Insider Selling Alerts - dars.gov.et

Sep 17, 2026

Sep 11, 2026

XORTX Therapeutics Inc (NASDAQ: XRTX) Stock Price, News & Analysis - kalkine.ca

Sep 11, 2026

XORTX Therapeutics Shares Rise 16.11% After HoursXORTX Therapeutics (NASDAQ:XRTX) - Benzinga

Sep 11, 2026

Sep 10, 2026

Xortx Therapeutics Inc Announces the Launch of Production of Drug Material and Tablet Manufacturing - marketscreener.com

Sep 10, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Sep 10, 2026

XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program - TipRanks

Sep 10, 2026

XORTX Therapeutics (XRTX) begins making new gout drug - Stock Titan

Sep 10, 2026

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ - The Manila Times

Sep 10, 2026

XORTX Therapeutics Initiates GMP Manufacturing of XORLO™ to Advance Gout Treatment Clinical Trials - Kalkine Media

Sep 10, 2026

Sep 09, 2026

XORTX Therapeutics (XRTX) commits $2.5M to investor outreach after TSXV delist - Stock Titan

Sep 09, 2026

Price to sales forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView

Sep 09, 2026

Price to earnings forward of XORTX Therapeutics Inc. – NASDAQ:XRTX - TradingView

Sep 09, 2026

EBITDA margin % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 09, 2026

Return on invested capital % of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 09, 2026

XORTX Therapeutics, Inc. Financial Statements – HAM:ANU - TradingView

Sep 09, 2026

Diluted shares outstanding of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 09, 2026

Sep 08, 2026

XORTX Re-Engages Investor Relations Program - markets.businessinsider.com

Sep 08, 2026

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile - TipRanks

Sep 08, 2026

XORTX Re-Engages Investor Relations Program - The Manila Times

Sep 08, 2026

XORTX Re-Engages Investor Relations Program - GlobeNewswire

Sep 08, 2026

XORTX Re-Engages Investor Relations Program - Moomoo

Sep 08, 2026

XORTX Therapeutics, Inc. Cash Flow – HAM:ANU - TradingView

Sep 08, 2026

XORTX Therapeutics (NASDAQ: XRTX) Signs New $2.5M Investor Relations Deal with IR Agency - kalkinemedia.com

Sep 08, 2026

Basic earnings per share (basic EPS) of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 08, 2026

XORTX Therapeutics, Inc. Balance Sheet – HAM:ANU - TradingView

Sep 08, 2026

XORTX Therapeutics, Inc. Earnings and Revenue – HAM:ANU - TradingView

Sep 08, 2026

Discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 08, 2026

XORTX Therapeutics, Inc. Statistics – HAM:ANU - TradingView

Sep 08, 2026

Net income before discontinued operations of XORTX Therapeutics, Inc. – HAM:ANU - TradingView

Sep 08, 2026

Sep 05, 2026

XORTX Therapeutics stock gains as Nasdaq listing takes center stage - ad-hoc-news.de

Sep 05, 2026

Sep 04, 2026